Researchers have developed a blood-based method that may help detect germ cell tumours, the most common type of testicular cancer, including cases that do not show up on standard blood tests, according to a study published in Nature Communications.

Testicular cancer most often affects adolescents and young adults, and it is highly treatable, especially when found early.

However, diagnosis can be challenging when tumours do not produce enough of the usual blood-based substances — called tumour markers — to show up on standard tests, which can make diagnosis harder.

To help solve this, researchers used a method that analyses thousands of immune system signals in the blood at once.

Using this approach, they developed a new test called GCT-iSIGN. In a study of 427 blood samples, the test identified 93% of individuals who had germ cell tumours and correctly ruled out cancer in 99% of people who did not.

The test also detected 23 of 24 cases that standard blood tests missed. This gives doctors another way to find these cancers, especially in younger patients.

Researchers also developed a second test, called Sem-iSIGN, designed to distinguish between two main types of testicular cancer. This distinction matters because each type can require a different treatment approach.

The findings build on earlier work by the same research teams using immune profiling to identify biomarkers linked to paraneoplastic neurologic syndrome associated with testicular cancer, including KLHL11 IgG, which was described previously in The New England Journal of Medicine.

"When standard blood markers are negative, diagnosis and treatment planning can be delayed," says Divyanshu Dubey, M.B.B.S., senior and corresponding author of the study and a professor of laboratory medicine and pathology and a professor of neurology at Mayo Clinic.

"Our findings show a promising path toward a more sensitive blood test approach, but additional studies are needed before it can be used routinely in patient care."

Article: Whole-proteome phage immunoprecipitation sequencing reveals germ cell tumor–specific immunosignature

Source: Mayo Clinic